7th Annual Symposium on Current Strategies in the Treatment of Hodgkin’s Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia

Saturday, June 23, 2018
7:00 AM - 4:00 PM

Program Chair
Fredrick Hagemeister, MD
Professor of Medicine,
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center,
Houston, TX

Educational Grants
Takeda Oncology
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Novartis Pharmaceuticals Corporation

For online registration and more information visit:
www.cancernetus.com

REGISTRATION FORM

First Name ___________________ Middle Initial _____ Last Name ______________________
[ ] Physician  [ ] Pa-C  [ ] NP  [ ] PhD  [ ] Pharmacist  [ ] Industry  [ ] Nurse  [ ] Other

Mailing Address ____________________________

City ___________________ State ______ Zip Code ____________

Phone ___________________ Fax ___________________

Email ___________________

Speciality ___________________

Registration Fee (Registration fee includes buffet breakfast, lunch and syllabus book.)

<table>
<thead>
<tr>
<th>Registration Fee</th>
<th>Early Registration Fee - Up to 5/31/18</th>
<th>Discounted Registration Fee - 6/1/18 - 6/15/18</th>
<th>Regular Registration Fee - 6/16/18 - 6/23/18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$100.00</td>
<td>$130.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Nurses, Nurse Practitioners, Physician Assistants</td>
<td>$75.00</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Pharmacists, Fellows</td>
<td>$75.00</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Industry †</td>
<td>$350.00</td>
<td>$400.00</td>
<td>$450.00</td>
</tr>
</tbody>
</table>

† Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

No refund; substitution is allowed.

Payment may be made:  [ ] MC  [ ] Visa  [ ] Discover  [ ] Check

Credit Card Number ___________________ Expiration Date __________

Name and address (as given on the monthly credit card statement) ____________________________

Pharmacist e-profile NABP#: ____________________ Pharmacist DOB (MMDD): __________

Signature _______________________

Register online at www.cancernetus.com

Please make checks payable to CancerNet. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, please call Brian Waggoner at 972-459-5222 or E-mail: brianw@cancernetus.com
Faculty

Jorge Cortes, MD
Professor and Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, TX

Nathan Fowler, MD
Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Fredrick B. Hagemeister, MD
Professor of Medicine, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Nitin Jain, MD
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Elisabet E. Manasanch, MD
Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Sattva S. Neelapu, MD
Professor of Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Robert Orlowski, MD, PhD
Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Farhad Ravandi, MD
Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

William G. Wierda, MD
Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

7th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia

Saturday, June 23, 2018

Houston Marriott at the Texas Medical Center
6580 Fannin Street, Houston, TX 77030
Phone: (713) 796-0080

Statement of Need / Program Overview

This symposium is intended to improve care of patients with Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

Target Audience

This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in hematological malignancies such as Hodgkin’s lymphoma, B-cell lymphoma, multiple myeloma and leukemia. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Learning Objectives

• Describe the biology and mechanism of action of CAR-T cells in hematological malignancies
• Evaluate the therapeutic efficacy and safety of axicabtagene ciloleucel, tisagenlecleucel and B-cell maturation antigen (BCMA) in patients with selected hematological malignancies
• Assess the efficacy and safety of PD-1 and PD-L1 blockade in combination with brentuximab vedotin and autologous stem cell and allogenic stem cell transplantation in patients with Hodgkin’s lymphoma HL
• Cite the newer treatment options for follicular lymphoma
• Identify the newer treatment options for mantle cell lymphoma
• Apply the novel treatment options for chronic lymphocytic lymphoma
• Identify benefit and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic therapy for patients with newly diagnosed active multiple myeloma (MM)
• Evaluate available data on the selection, sequencing and/or combination of novel therapeutic agents in the treatment of patients with relapsed/refractory MM
• Evaluate the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with acute lymphoblastic leukemia
• Evaluate how compound genotypes are related to novel therapeutic option based outcomes in patients with acute myeloid leukemia
• Identify response assessment and management of tyrosine kinase inhibitor resistance in the treatment of chronic myeloid leukemia
### Agenda

**7th Annual Symposium on Current Strategies in the Treatment of Hodgkin’s Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Pre-registration (Buffet Breakfast)</td>
<td></td>
</tr>
<tr>
<td>8:25 AM</td>
<td>Welcome and Introductions</td>
<td>Fredrick Hagemeister, MD</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Pretest - Case Report Vignettes</td>
<td>Sattva S. Neelapu, MD / Fredrick Hagemeister, MD</td>
</tr>
<tr>
<td>8:40 AM</td>
<td>Overview of Biology and Mechanism of Action of CAR T-cells and Potential</td>
<td>Sattva S. Neelapu, MD</td>
</tr>
<tr>
<td></td>
<td>Therapeutic Efficacy in Selected Hematological Malignancies</td>
<td></td>
</tr>
<tr>
<td>9:05 AM</td>
<td>Overview of Immunotherapy and Combination Therapy Options for Hodgkin's</td>
<td>Fredrick Hagemeister, MD</td>
</tr>
<tr>
<td></td>
<td>Lymphoma</td>
<td></td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Posttest - Case Report Vignettes</td>
<td>Sattva S. Neelapu, MD / Fredrick Hagemeister, MD</td>
</tr>
<tr>
<td>9:40 AM</td>
<td>Pretest - Case Report Vignettes</td>
<td>Fredrick Hagemeister, MD / Nathan Fowler, MD</td>
</tr>
<tr>
<td>9:50 AM</td>
<td>Overview of Treatment Options for Diffuse Large Cell Lymphoma (DLCL)</td>
<td>Fredrick Hagemeister, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Overview of Treatment Options for Follicular Lymphoma (FL)</td>
<td>Nathan Fowler, MD</td>
</tr>
<tr>
<td>10:55 AM</td>
<td>Pretest - Case Report Vignettes</td>
<td>Fredrick Hagemeister, MD / Nathan Fowler, MD</td>
</tr>
<tr>
<td>11:05 AM</td>
<td>Pretest - Case Report Vignettes</td>
<td>TBD / William Wierda, MD</td>
</tr>
<tr>
<td>11:15 AM</td>
<td>Overview of Treatment Options for Mantle Cell Lymphoma (MCL)</td>
<td></td>
</tr>
<tr>
<td>11:40 AM</td>
<td>Overview of Treatment Options for Chronic Lymphocytic Leukemia (CLL)</td>
<td>William Wierda, MD</td>
</tr>
<tr>
<td>12:05 PM</td>
<td>Posttest - Case Report Vignettes</td>
<td>TBD / William Wierda, MD</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>LUNCH</td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Pretest - Case Report Vignettes</td>
<td>Elisabet Manasanch, MD / Robert Orlowski, MD, PhD</td>
</tr>
<tr>
<td>1:10 PM</td>
<td>An Overview on Systemic Therapy for Patients with Newly Diagnosed</td>
<td>Elisabet Manasanch, MD</td>
</tr>
<tr>
<td></td>
<td>Active Multiple Myeloma (MM)</td>
<td></td>
</tr>
<tr>
<td>1:35 PM</td>
<td>Outline the Selection, Sequencing and/or Combination of Novel Therapies</td>
<td>Robert Orlowski, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>for Patients with Relapsed/refractory MM</td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Posttest - Case Report Vignettes</td>
<td>Elisabet Manasanch, MD / Robert Orlowski, MD, PhD</td>
</tr>
<tr>
<td>2:10 PM</td>
<td>Pretest - Case Report Vignettes</td>
<td>Nitin Jain, MD / Farhad Ravandi, MD / Jorge Cortes, MD</td>
</tr>
<tr>
<td>2:20 PM</td>
<td>Novel Therapies for adolescents and young adults (AYA), Philadelphia-posit</td>
<td>Nitin Jain, MD</td>
</tr>
<tr>
<td></td>
<td>ive Relapsed/Refractory Patients with Acute Lymphoblastic Leukemia</td>
<td></td>
</tr>
<tr>
<td>2:45 PM</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td>How Compound Genotypes are Related to Novel Therapy Based Outcomes</td>
<td>Farhad Ravandi, MD</td>
</tr>
<tr>
<td></td>
<td>in Patients with Acute Myeloid Leukemia?</td>
<td></td>
</tr>
<tr>
<td>3:25 PM</td>
<td>Response Assessment and Management of Tyrosine Kinase Inhibitors</td>
<td>Jorge Cortes, MD</td>
</tr>
<tr>
<td></td>
<td>Resistance in the Management of Patients with Chronic Myeloid Leukemia</td>
<td></td>
</tr>
<tr>
<td>3:50 PM</td>
<td>Posttest - Case Report Vignettes</td>
<td>Nitin Jain, MD / Farhad Ravandi, MD / Jorge Cortes, MD</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Closing Remarks and Adjourn</td>
<td>Fredrick Hagemeister, MD</td>
</tr>
</tbody>
</table>

### Physicians / Nurses / Pharmacists

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement - Amedco LLC designates this live activity for a maximum of 6 **AMA PRA Category 1 Credits™** for physicians, 6 contact hours for nurses and 6 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Participants may reserve guest rooms by calling (713) 796-0080